Abbott surprises a few with spin-off but do the plans go far enough?
Abbott’s plan to break itself up into two businesses – one for medical products and one for research pharmaceuticals – has suddenly got the analysts’ thinking caps on.
Barely a moment after the surprise news went public, the talk was on the future of both businesses and their chances of survival. Overall, the changes have been welcomed and represent a key moment in the 123 year old company’s history. It’s been there before, on a smaller scale of course, with the formation and successful spin-off of its hospital products business into Hospira in 2007, which has since enjoyed strong growth.
Both of Abbott’s divisions have grown in stature and offer contrasting demands in terms of resources so the split into two businesses is bound to improve clarity amongst the investment community. The medical products business will have 2011 revenues of approximately US$22 billion and the research-based pharma unit will have an estimated US$18 billion sales turnover. However, without the protection of the other, both companies could swiftly find themselves the target of deal makers.
With clarity comes opportunity. Abbott’s upstart research business finds itself just outside of the biggest players of the pharmaceutical market, but with a hot drug on its hands in the form of Humira – an anti-inflammatory drug that posted sales of US$6.5 million in 2010. In a market where the focus is on product pipelines, particularly blockbuster ones, the unnamed Abbott business has a relatively strong pipeline.
Whilst the spin-off is impressively detailed, there’s the nagging doubt that the company, like Johnson & Johnson, continues to find it hard to break up the relationship of medical devices and pharmaceuticals, a model long since ditched by the likes of Bristol-Myers Squibb, Allergan and Pfizer. The medical device business, which is particularly strong in cardiovascular devices and ophthalmic products, sits uneasily amongst the slightly larger divisions of generics, and nutritional products. Whilst Generics enjoys double-digit sales growth, such targets remain elusive in the medical device field for Abbott.
Still, Rome wasn’t built in a day and the spin-off plan is likely to keep investors happy for the moment at least. The company has shown in recent times that it isn’t afraid of ditching certain markets if it feels warranted. The company’s ruthless and swift exit from the spine market when the going got too tough being a classic case in mind.
Whilst this blog is not saying that Abbott’s commitment to medical devices is likely to wane in the short-term – the current spin-off alone will take at least a year to complete at least, but one wonders how long it will take before investors start questioning to rationale of keeping a medical device/pharma mix over the long term. Would an opportunistic offer from Medtronic or an attractive offer from a private equity group change things? One suspects that all the time the company keeps posting sales growth and delivers the financial numbers, Abbott’s investors won’t mind a bit either way.
Thanks to Lawrence Miller for providing this article, Lawrence is Espicom’s medical newsletter team leader and editor of Medical Industry Week
- Non-Surgical Treatment for Varicose Veins (medical-technologyblog.com)
- Drug Delivery Insight – Celtic leads the way in launch of Anglo-Russian pharma firm (medical-technologyblog.com)
- Flutiform Presents Good Safety Profile in Asthma Patients (medical-technologyblog.com)
Tagged with: abbot spinoff • abbott • abbott allergan • abbott and allergan • abbott cordis • abbott diagnostics blog • Abbott Laboratories • abbott laboratories blogs • abbott laboratories medical products growth • abbott medical spin off • abbott ophtalmic spin off • abbott pharma spin off rumor 2010 • abbott rationale • abbott spin • abbott spin off • abbott spin off 2011 • abbott spin off rationale • abbott spin offs • abbott spinning off devices • abbott spinnoff • abbott spinoff • abbott spinoff diagnostics • abbott to spin hospital products • abbott vs allergan • abbott+spin+off+2011 • Allergan • allergan abbott • allergan and abbott • allergan and abott • allergan blog • allergan entering varicose market • allergan spilt into 2 copanys • allergan spin off • allograft business rumors • allograft testing for stds • allografts std • boston scientific + absorbable stent • boston scientific reva absorbable stent • break up jnj • bristol myers or abott • bristol myers squibb & abbott • bristol myers squibb devices • bristol myers squibb medical device • bristol myers squibb medical devices • Bristol-Myers Squibb • bristol-myers squibb medical device sales • Business • cordis abbott • covidien pharma spin off rumor • Covidien rumor • covidien rumors • covidien sale varicose business • covidien spinoff rumors pharma • did abbott buy allergan? • did medtronic purchase allergan? • Hospira • hospira blog • hospira revenues when spun oFf • j&j marketing spin offs • jnj spin offs • jnj spinoffs • jnj split up • Johnson & Johnson • johnson & johnson spin off • johnson and johnson • johnson and johnson breakup spinoff • johnson and johnson spin off • johnson and johnson spin-off history • johnson and johnson spinoff • johson and johson spin off • medical device rumors • Medical Industry Week • medical supplies business blogs • medical technologies that failed • Medical Technology • medical technology spin off • medical technology that failed • Medtronic • medtronic current supplies • medtronic dealmakers • medtronic foot and ankle • medtronic foot and ankle supplies • medtronic foot ankle • medtronic purchase • medtronic spine spinoff 2012 • medtronic spun off from • medtronic turnover • medtronic turnover 2012 • medtronic turnover target for 2012 • medtronics blogs current • medtronics turnover • pharma rumors • pharmaceutical spin off rumors • rationale for abbott spin off • reva absorbable stent • reva failed absorbable stent • reva resorbable • rumors covidien • rumors in medical device • rumors pharma blog • smiths medical spinoff • spin offs • spinoff rationale • spinoffs from jnj • squibb device • start up absorbable stent • tier level 4 osteotech premier agreement • when will abbott spin off
Filed under: Company News
Like this post? Subscribe to my RSS feed and get loads more!